SPRY Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of -116.82%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Agenus, Inc.'s return on equity of --.

ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 208.71%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 267.06%. Given that Agenus, Inc. has higher upside potential than ARS Pharmaceuticals, Inc., analysts believe Agenus, Inc. is more attractive than ARS Pharmaceuticals, Inc..

ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.

ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are larger than Agenus, Inc. quarterly revenues of $30.2M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Agenus, Inc.'s net income of $63.9M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.43x versus 0.85x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 16.99%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 208.71%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.97%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 146.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.43x versus 11.91x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 47.99%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 208.71%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.34%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Krystal Biotech, Inc.'s PE ratio is 40.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.43x versus 21.25x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of -157.38% compared to ARS Pharmaceuticals, Inc.'s net margin of 16.21%. ARS Pharmaceuticals, Inc.'s return on equity of -38.98% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.

ARS Pharmaceuticals, Inc. has a consensus price target of $28.83, signalling upside risk potential of 208.71%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $666.46 which suggests that it could grow by 28.14%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Thermo Fisher Scientific, Inc..

ARS Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.277% less volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.928, suggesting its less volatile than the S&P 500 by 7.166%.

ARS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.33% to investors and pays a quarterly dividend of $0.43 per share. ARS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ARS Pharmaceuticals, Inc. quarterly revenues are $32.5M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. ARS Pharmaceuticals, Inc.'s net income of -$51.2M is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, ARS Pharmaceuticals, Inc.'s price-to-earnings ratio is 174.21x while Thermo Fisher Scientific, Inc.'s PE ratio is 29.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARS Pharmaceuticals, Inc. is 6.43x versus 4.41x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.